Today: 23 January 2026
Subscribe
Browse Category

Health News News 12 August 2025 - 20 August 2025

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the news cycle.) Public Health & Policy Highlights Sources: Key information in this report is drawn from reputable industry and news…
20 August 2025
··
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia, the first new fibromyalgia therapy…
16 August 2025
···
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral DPP-1 inhibitor for chronic respiratory diseases, in a pact potentially worth up to $645 million including…
12 August 2025
·
1 2 3 4

Stock Market Today

  • Apple Stock Outlook: Growth, AI Adoption, and Market Position
    January 23, 2026, 12:18 PM EST. Apple (AAPL) has delivered remarkable long-term returns, with shares soaring over 900% in the past decade. The company's strong product lineup, particularly the iPhone, helped it claim the top spot in the 2025 smartphone market with a 20% share. Despite recent underperformance versus the S&P 500 due to slow initial AI adoption and tariff concerns tied to its China supply chain, Apple is accelerating its AI integration and benefiting from U.S. tariff exemptions related to domestic production investments. Growth in shipments and improved return on invested capital point to effective investment strategies. Investors eyeing potential catalysts this year may find Apple's evolving AI efforts and stabilizing trade environment a solid basis for future gains.
Go toTop